http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 23 Jun 2026 09:18:27 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Haisco+licenses+two+drug+candidates+to+Nuvectis+for+up+to+%241.46B/26677132.html <p>Haisco Pharmaceutical Group Co., Ltd. (ticker: 002653) announced it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company, granting rights to develop, manufacture, and commercialize two of Haisco's drug candidates outside of Greater China.</p> <p>Under the agreement, Nuvectis receives exclusive worldwide rights, excluding Greater China, to HSK42360, a BRAF paradoxical breaker inhibitor currently in Phase I clinical trials in China. Nuvectis also receives rights to HSK39297, a CFB inhibitor, worldwide excluding Greater China, India, and certain Southeast Asia territories. Two new drug applications for HSK39297 in paroxysmal nocturnal hemoglobinuria have been submitted in China.</p> <p>Haisco will receive an http://www.streetinsider.com/Corporate+News/Haisco+licenses+two+drug+candidates+to+Nuvectis+for+up+to+%241.46B/26677132.html Tue, 23 Jun 2026 09:18:27 -0400 002653 O.13064183 http://www.streetinsider.com/Corporate+News/Haisco+licenses+two+drug+candidates+to+Nuvectis+for+up+to+%241.46B/26677132.html <p>Haisco Pharmaceutical Group Co., Ltd. (ticker: 002653) announced it has entered into an exclusive licensing agreement with Nuvectis, a U.S. biotechnology company, granting rights to develop, manufacture, and commercialize two of Haisco's drug candidates outside of Greater China.</p> <p>Under the agreement, Nuvectis receives exclusive worldwide rights, excluding Greater China, to HSK42360, a BRAF paradoxical breaker inhibitor currently in Phase I clinical trials in China. Nuvectis also receives rights to HSK39297, a CFB inhibitor, worldwide excluding Greater China, India, and certain Southeast Asia territories. Two new drug applications for HSK39297 in paroxysmal nocturnal hemoglobinuria have been submitted in China.</p> <p>Haisco will receive an http://www.streetinsider.com/Corporate+News/Haisco+licenses+two+drug+candidates+to+Nuvectis+for+up+to+%241.46B/26677132.html Tue, 23 Jun 2026 09:18:27 -0400 002653 O.13064183 http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- On <chron>June 23, 2026</chron> (<location value="LU/cn..beijng" idsrc="xmltag.org" >Beijing</location> time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with <span id="spanHghlt794d">Nuvectis, a</span> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize its independently developed innovative drug HSK42360 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, as well as its independently developed innovative drug HSK39297 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, <location value="LC/in" idsrc="xmltag.org" >India</location>, and certain <location value="LR/asp" http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html Tue, 23 Jun 2026 09:17:00 -0400 002653 O.13064183 http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- On <chron>June 23, 2026</chron> (<location value="LU/cn..beijng" idsrc="xmltag.org" >Beijing</location> time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with <span id="spanHghlt794d">Nuvectis, a</span> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize its independently developed innovative drug HSK42360 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, as well as its independently developed innovative drug HSK39297 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, <location value="LC/in" idsrc="xmltag.org" >India</location>, and certain <location value="LR/asp" http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html Tue, 23 Jun 2026 09:17:00 -0400 002653 O.13064183 http://www.streetinsider.com/PRNewswire/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- On <chron>June 23, 2026</chron> (<location value="LU/cn..beijng" idsrc="xmltag.org" >Beijing</location> time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with <span id="spanHghlt794d">Nuvectis, a</span> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize its independently developed innovative drug HSK42360 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, as well as its independently developed innovative drug HSK39297 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, <location value="LC/in" idsrc="xmltag.org" >India</location>, and certain <location value="LR/asp" http://www.streetinsider.com/PRNewswire/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html Tue, 23 Jun 2026 09:17:00 -0400 002653 O.13064183 http://www.streetinsider.com/PRNewswire/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 23, 2026</chron></span> /PRNewswire/ -- On <chron>June 23, 2026</chron> (<location value="LU/cn..beijng" idsrc="xmltag.org" >Beijing</location> time), Haisco Pharmaceutical Group Co., Ltd. (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with <span id="spanHghlt794d">Nuvectis, a</span> <location value="LC/us" idsrc="xmltag.org" >U.S</location>. biotechnology company. Under the agreement, Haisco has granted Nuvectis the exclusive rights to develop, manufacture, and commercialize its independently developed innovative drug HSK42360 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, as well as its independently developed innovative drug HSK39297 worldwide, excluding <location value="LC/cn" idsrc="xmltag.org" >Greater China</location>, <location value="LC/in" idsrc="xmltag.org" >India</location>, and certain <location value="LR/asp" http://www.streetinsider.com/PRNewswire/Haisco+Enters+into+Exclusive+License+Agreement+with+Nuvectis+for+Two+Drug+Candidates+in+Oncology+and+Complement+Indications/26677131.html Tue, 23 Jun 2026 09:17:00 -0400 002653 O.13064183 http://www.streetinsider.com/Press+Releases/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html <div class="xn-content"> <p><span class="legendSpanClass">SILICON VALLEY, Calif. and <location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- On <chron>May 29, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeutic areas.</p> <p>Under the agreement, Haisco will be responsible for the discovery and identification of up to five innovative target programs, while Lilly will lead IND-enabling studies, clinical development, and commercialization. Lilly will obtain exclusive worldwide rights to certain programs, and exclusive rights outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location>, <location value="LC/hk" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html Mon, 01 Jun 2026 05:50:00 -0400 002653 O.13064183 http://www.streetinsider.com/Press+Releases/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html <div class="xn-content"> <p><span class="legendSpanClass">SILICON VALLEY, Calif. and <location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- On <chron>May 29, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeutic areas.</p> <p>Under the agreement, Haisco will be responsible for the discovery and identification of up to five innovative target programs, while Lilly will lead IND-enabling studies, clinical development, and commercialization. Lilly will obtain exclusive worldwide rights to certain programs, and exclusive rights outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location>, <location value="LC/hk" idsrc="xmltag.org" http://www.streetinsider.com/Press+Releases/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html Mon, 01 Jun 2026 05:50:00 -0400 002653 O.13064183 http://www.streetinsider.com/PRNewswire/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html <div class="xn-content"> <p><span class="legendSpanClass">SILICON VALLEY, Calif. and <location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- On <chron>May 29, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeutic areas.</p> <p>Under the agreement, Haisco will be responsible for the discovery and identification of up to five innovative target programs, while Lilly will lead IND-enabling studies, clinical development, and commercialization. Lilly will obtain exclusive worldwide rights to certain programs, and exclusive rights outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location>, <location value="LC/hk" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html Mon, 01 Jun 2026 05:50:00 -0400 002653 O.13064183 http://www.streetinsider.com/PRNewswire/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html <div class="xn-content"> <p><span class="legendSpanClass">SILICON VALLEY, Calif. and <location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- On <chron>May 29, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> ("Haisco") (Ticker Code: 002653) announced a licensing and research collaboration with Eli Lilly and Company ("Lilly") to develop innovative medicines across multiple therapeutic areas.</p> <p>Under the agreement, Haisco will be responsible for the discovery and identification of up to five innovative target programs, while Lilly will lead IND-enabling studies, clinical development, and commercialization. Lilly will obtain exclusive worldwide rights to certain programs, and exclusive rights outside mainland <location value="LC/cn" idsrc="xmltag.org" >China</location>, <location value="LC/hk" idsrc="xmltag.org" http://www.streetinsider.com/PRNewswire/Haisco+Announces+Licensing+and+Research+Collaboration+Agreement+with+Lilly+to+Develop+Innovative+Medicines+Across+Multiple+Therapeutic+Areas/26578117.html Mon, 01 Jun 2026 05:50:00 -0400 002653 O.13064183 http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/Press+Releases/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group</span>, has officially received marketing approval from the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA), becoming the first <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative intravenous anesthetic to enter the global market. This milestone marks the moment a <location value="LC/cn" idsrc="xmltag.org" >China</location>-originated innovative drug, backed by outstanding breakthroughs and robust clinical evidence, has officially opened the door to the global high-standard pharmaceutical market and secured its entry ticket.</p> <p>Intravenous anesthetics are http://www.streetinsider.com/PRNewswire/China%27s+Original+Innovative+Drug+Cipepofol+Approved+for+Marketing+by+the+U.S.+FDA/26577807.html Mon, 01 Jun 2026 03:04:00 -0400 002653 A.06822034 O.13064183 O.20026344 http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html <p>Haisco Pharmaceutical Group Co., Ltd. (Shenzhen: 002653) announced on April 10 that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV) for the development of pain medicines.</p> <p>Under the agreement, Haisco grants AbbVie exclusive rights to develop, manufacture, and commercialize novel pain treatment compounds globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds currently at various development stages in China, ranging from preclinical to Phase 1 clinical development.</p> <p>Haisco will receive an upfront payment of $30 million and is eligible to receive up to $715 million in aggregate development, regulatory, and commercial milestone payments. The http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html Mon, 13 Apr 2026 02:25:05 -0400 002653 ABBV O.13064183 O.14731390 http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html <p>Haisco Pharmaceutical Group Co., Ltd. (Shenzhen: 002653) announced on April 10 that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV) for the development of pain medicines.</p> <p>Under the agreement, Haisco grants AbbVie exclusive rights to develop, manufacture, and commercialize novel pain treatment compounds globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds currently at various development stages in China, ranging from preclinical to Phase 1 clinical development.</p> <p>Haisco will receive an upfront payment of $30 million and is eligible to receive up to $715 million in aggregate development, regulatory, and commercial milestone payments. The http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html Mon, 13 Apr 2026 02:25:05 -0400 002653 ABBV O.13064183 O.14731390 http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html <p>Haisco Pharmaceutical Group Co., Ltd. (Shenzhen: 002653) announced on April 10 that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV) for the development of pain medicines.</p> <p>Under the agreement, Haisco grants AbbVie exclusive rights to develop, manufacture, and commercialize novel pain treatment compounds globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds currently at various development stages in China, ranging from preclinical to Phase 1 clinical development.</p> <p>Haisco will receive an upfront payment of $30 million and is eligible to receive up to $715 million in aggregate development, regulatory, and commercial milestone payments. The http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html Mon, 13 Apr 2026 02:25:05 -0400 002653 ABBV O.13064183 O.14731390 http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html <p>Haisco Pharmaceutical Group Co., Ltd. (Shenzhen: 002653) announced on April 10 that it has entered into an exclusive licensing agreement with AbbVie (NYSE: ABBV) for the development of pain medicines.</p> <p>Under the agreement, Haisco grants AbbVie exclusive rights to develop, manufacture, and commercialize novel pain treatment compounds globally, excluding mainland China, Hong Kong, and Macau. The program includes multiple compounds currently at various development stages in China, ranging from preclinical to Phase 1 clinical development.</p> <p>Haisco will receive an upfront payment of $30 million and is eligible to receive up to $715 million in aggregate development, regulatory, and commercial milestone payments. The http://www.streetinsider.com/Corporate+News/Haisco+signs+exclusive+pain+medicine+license+deal+with+AbbVie/26301680.html Mon, 13 Apr 2026 02:25:05 -0400 002653 ABBV O.13064183 O.14731390 http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+AbbVie+to+Develop+Novel+Medicines+for+Pain/26301679.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>April 13, 2026</chron></span> /PRNewswire/ -- On <chron>April 10, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with <span value="NYSE:ABBV" idsrc="xmltag.org">AbbVie</span> (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants <span value="NYSE:ABBV" idsrc="xmltag.org">AbbVie</span> the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland <location value="LC/cn" idsrc="xmltag.org" >China</location>, <location value="LC/hk" idsrc="xmltag.org" >Hong Kong</location>, and <location value="LC/mo" idsrc="xmltag.org" >Macau</location>.</p> <p>The program includes multiple compounds designed to address pain-related indications. These compounds are currently at http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+AbbVie+to+Develop+Novel+Medicines+for+Pain/26301679.html Mon, 13 Apr 2026 02:24:00 -0400 002653 ABBV O.13064183 O.14731390 http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+AbbVie+to+Develop+Novel+Medicines+for+Pain/26301679.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>April 13, 2026</chron></span> /PRNewswire/ -- On <chron>April 10, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with <span value="NYSE:ABBV" idsrc="xmltag.org">AbbVie</span> (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants <span value="NYSE:ABBV" idsrc="xmltag.org">AbbVie</span> the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland <location value="LC/cn" idsrc="xmltag.org" >China</location>, <location value="LC/hk" idsrc="xmltag.org" >Hong Kong</location>, and <location value="LC/mo" idsrc="xmltag.org" >Macau</location>.</p> <p>The program includes multiple compounds designed to address pain-related indications. These compounds are currently at http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+AbbVie+to+Develop+Novel+Medicines+for+Pain/26301679.html Mon, 13 Apr 2026 02:24:00 -0400 002653 ABBV O.13064183 O.14731390 http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+AbbVie+to+Develop+Novel+Medicines+for+Pain/26301679.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/cn..beijng" idsrc="xmltag.org" >BEIJING</location></span>, <span class="legendSpanClass"><chron>April 13, 2026</chron></span> /PRNewswire/ -- On <chron>April 10, 2026</chron>, <span value="Shenzhen:002653" idsrc="xmltag.org" >Haisco Pharmaceutical Group Co., Ltd.</span> (Ticker Code: 002653) announced that it has entered into an exclusive licensing agreement with <span value="NYSE:ABBV" idsrc="xmltag.org">AbbVie</span> (NYSE: ABBV), a global biopharmaceutical company. Under the agreement, Haisco grants <span value="NYSE:ABBV" idsrc="xmltag.org">AbbVie</span> the exclusive rights to develop, manufacture, and commercialize novel medicines for the treatment of pain globally, excluding mainland <location value="LC/cn" idsrc="xmltag.org" >China</location>, <location value="LC/hk" idsrc="xmltag.org" >Hong Kong</location>, and <location value="LC/mo" idsrc="xmltag.org" >Macau</location>.</p> <p>The program includes multiple compounds designed to address pain-related indications. These compounds are currently at http://www.streetinsider.com/Press+Releases/Haisco+Enters+into+Exclusive+License+Agreement+with+AbbVie+to+Develop+Novel+Medicines+for+Pain/26301679.html Mon, 13 Apr 2026 02:24:00 -0400 002653 ABBV O.13064183 O.14731390